Xevinapant placebo clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
EORTC 2120-HNCG: Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck squamous cell carcinoma: a randomized phase II study (Ravina)
This study looks at a new drug, xevinapant, given with radiotherapy for older patients with advanced head and neck cancer. We want to see if this combination helps more people live longer without their cancer coming back. It's a Phase II study, meaning we're testing its effectiveness and safety.
For: Squamous cell carcinoma of head and neckItaly · Slovenia · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A double-blind randomized, Phase III study of radiotherapy combined with cetuXimab + Xevinapant compared to radiotherapy combined with cetuximab (Standard of care) + placebo in patients with Locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN), unfit for high-dose cisplatin (XXL study)
This study compares a new drug, xevinapant, plus standard treatment for an advanced form of head and neck cancer. Researchers want to see if adding xevinapant helps patients live longer without their cancer getting worse, compared to the standard treatment alone.
For: Locally advanced squamous cell carcinoma of the head and neckFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high-risk for relapse and are ineligible for high-dose cisplatin
This study looks at a new medicine called xevinapant, given with radiotherapy, for people who have had surgery for head and neck cancer. It compares this treatment to radiotherapy with a dummy medicine, to see if xevinapant helps prevent the cancer from coming back.
For: Resected squamous cell carcinoma of the head and neckGreece · Austria · Belgium